{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:00Z","timestamp":1790732940636,"version":"4.1.0"},"reference-count":121,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:p>Several direct\u2010acting antiviral agents (DAAs) have marketing authorization in Europe and in the USA and have changed the landscape of hepatitis C treatment: each DAA has its own metabolism and drug\u2013drug interactions (DDIs), and managing them is a challenge. To compile the pharmacokinetics and DDI data of the new DAA and to provide a guide for management of DDI. An indexed MEDLINE search was conducted using the keywords: DAA, hepatitis C, simeprevir, daclatasvir, ledipasvir, sofosbuvir, 3D regimen (paritaprevir\/ritonavir, ombitasvir, dasabuvir), DDI and pharmacokinetics. Data were also collected from hepatology, and infectious disease and clinical pharmacology conferences abstracts. Food can play a role in the absorption of DAAs. Most of the interactions are linked to metabolism (cytochrome P450\u20103\u00a0A4 [CYP3A4]) or hepatic and\/or intestinal transporters (organic anion\u2010transporting polypeptide and P\u2010glycoprotein [P\u2010gp]). To a lesser extent other pathways can be involved such as breast cancer resistance protein transporter or UDP\u2010glucuronosyltransferase metabolism. DDI are more likely to occur with 3D regimen, daclatasvir, simeprevir and ledipasvir, as they are all both substrates and inhibitors of P\u2010gp and\/or CYP3A4, than with sofosbuvir. They can increase concentrations of coadministered drugs and their concentrations may be influenced by P\u2010gp or CYP3A4 inducers or inhibitors. Overdosage or low dosage can be encountered with potent inducers or inhibitors of CYP3A4 or drugs with a narrow therapeutic range. The key to interpret DDI data is a good understanding of the pharmacokinetic profiles of the drugs involved. Their ability to inhibit CYP450\u20103A4 and transporters (hepatic and\/or intestinal) can have significant clinical consequences.<\/jats:p>","DOI":"10.1111\/bcp.13095","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T02:56:41Z","timestamp":1471402601000},"page":"269-293","source":"Crossref","is-referenced-by-count":64,"title":["Managing drug\u2013drug interactions with new direct\u2010acting antiviral agents in chronic hepatitis C"],"prefix":"10.1111","volume":"83","author":[{"given":"Sarah","family":"Talavera Pons","sequence":"first","affiliation":[{"name":"Service de Pharmacie Centre Hospitalier Universitaire  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Boyer","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Centre Hospitalier Universitaire  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Lamblin","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Digestive et H\u00e9pato\u2010biliaire Centre Hospitalier Universitaire Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Chennell","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Centre Hospitalier Universitaire  Clermont\u2010Ferrand France"},{"name":"EA 4676 C\u2010Biosenss Universit\u00e9 d'Auvergne  Clermont\u2010Ferrand Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois\u2010Thibault","family":"Ch\u00e2tenet","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Centre Hospitalier Universitaire  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Digestive et H\u00e9pato\u2010biliaire Centre Hospitalier Universitaire Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Sautou","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Centre Hospitalier Universitaire  Clermont\u2010Ferrand France"},{"name":"EA 4676 C\u2010Biosenss Universit\u00e9 d'Auvergne  Clermont\u2010Ferrand Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Abergel","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Digestive et H\u00e9pato\u2010biliaire Centre Hospitalier Universitaire Estaing  Clermont\u2010Ferrand France"},{"name":"Unit\u00e9 Mixte de Recherche Universit\u00e9 d'Auvergne, CNRS 6284 University of Clermont\u2010Ferrand  France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1037"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13354"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13355"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.027"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12774"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12718"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.66"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02724-14"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.106"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000152"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12523"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1679-9"},{"key":"e_1_2_8_14_1","unstructured":"Ouwerkerk\u2010MahadevanS SimionA MortierS PeetersM Beaumont\u2010MauvielM.The effect of food and different meal types on the bioavailability of simeprevir (TMC435) an HCV protease inhibitor in clinical development. [poster no. 0_20] [Abstract presented at the 8th international workshop on clinical pharmacology of hepatitis therapy]. Cambridge MA 2013."},{"key":"e_1_2_8_15_1","unstructured":"KirbyB GordiT SymondsWT KearneyBP MathiasA.Population pharmacokinetics of sofosbuvir and its major metabolite (GS\u2010331007) in healthy and HCV\u2010infected adult subjects. [Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases]. Washington DC 2013."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0261-7"},{"key":"e_1_2_8_17_1","unstructured":"GermanP YangJ WestS HanL SajwaniK MathiasA.Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir\/sofosbuvir fixed dose combination tablet.[Abstract P_15] [Abstract presented at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy]. Washington DC 2014."},{"key":"e_1_2_8_18_1","unstructured":"TerraultN ZeuzemS Di BisceglieAM LimJK PockrosPJ FrazierLM et al.Treatment outcomes with 8 12 and 24\u00a0week regimens of ledipasvir\/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective observational study. [Abstract presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2015."},{"key":"e_1_2_8_19_1","unstructured":"EleyT YouX WangR LuoW\u2010L HuangS KandoussiH et al.Daclatasvir: overview of drug\u2013drug interactions with antiretroviral agents and other common concomitant drugs [Abstract presented at the HIV DART]. Miami FL 2014."},{"key":"e_1_2_8_20_1","unstructured":"Abbvie Corporation.Viekira Pak (ombitasvir paritaprevir and ritonavir tablets; dasabuvir tablets) Prescribing Information. North Chicago IL December 2014. In."},{"key":"e_1_2_8_21_1","unstructured":"MenonRM KleinCE LawalAL LawalA ChiuYL AwniWM et al.Pharmacokinetics safety and tole rability of the HCV protease inhibitor ABT\u2010450 with ritonavir following multiple ascending doses in healthy adult volunteers. [abstract 58] [Abstract presented at the HepDART]. Hawaii USA 2009."},{"key":"e_1_2_8_22_1","unstructured":"Gilead.Harvoni (sofosbuvir\/ledipasvir) Summary of Product Characteristics. European Union 2014."},{"key":"e_1_2_8_23_1","unstructured":"Janssen\u2010Cilag.Olysio (simeprevir) Summary of Product Characteristics. European Union 2014."},{"key":"e_1_2_8_24_1","unstructured":"Bristol\u2010Myers\u2010Squibb.Daklinza (daclatasvir) Summary of Product Characteristics. European Union 2014."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121829"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342010-00003"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055558"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.113.007518"},{"key":"e_1_2_8_29_1","unstructured":"HuismanMT SnoeysJ MonbaliuJ MartensM SekarV RaoofA.In vitrostudies investigating the mechanism of interaction between TMC435 and hepatic transporters. [Poster 278] [Abstract presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston USA 2010."},{"key":"e_1_2_8_30_1","unstructured":"GermanP PangP WestS HanL SajwaniK MathiasA.Drug interactions between direct acting anti\u2010HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. [abstract O_06] [Abstract presented at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy.]. Washington DC 2014."},{"key":"e_1_2_8_31_1","unstructured":"GermanP PangP FangL ChungD MathiasA.Drug\u2013drug interaction profile of the fixed\u2010dose combination tablet ledipasvir\/sofosbuvir. [Abstract 1976] [Abstract presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2014."},{"key":"e_1_2_8_32_1","unstructured":"GarrisonK WangY BrainardD.The effect of rifampin on the pharmacokinetics of sofosbuvir in healthy volunteers. [abstract 992] [Abstract presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2014."},{"key":"e_1_2_8_33_1","unstructured":"Ouwerkerk\u2010MahadevanS SimionA PeetersM BeaumontM.Summary of pharmacokinetic drug\u2013drug interactions for simeprevir (TMC435) a hepatitis C virus Ns3\/4\u00a0A protease inhibitor. [abstract PE 10\/7] [Abstract presented at the 14th European AIDS Conference]. Brussels Belgium 2013."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.026"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.10.001"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062174"},{"key":"e_1_2_8_38_1","unstructured":"Gilead.Sovaldi (sofosbuvir) Summary of Product Characteristics. European Union 2014.ldi. In."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2009.07.009"},{"key":"e_1_2_8_40_1","unstructured":"DenningJ CornpropstM ClemonsD FangL SaleM BerreyMM et al.Lack of effect of the nucleotide analog polymerase inhibitor PSI\u20107977 on methadone pharmacokinetics and pharmacodynamics. [abstract 372] [Abstract presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. San Francisco USA 2011."},{"key":"e_1_2_8_41_1","unstructured":"MathiasA CornpropstM ClemonsD DenningJ SymondsWT.No clinically significant pharmacokinetic drug\u2013drug interactions between sofosbuvir (GS\u20107977) and the immuno suppressants cyclosporine A or tacrolimus in healthy volunteers. [abstract 1869] [Abstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2012."},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0142-5"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.346"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.001"},{"key":"e_1_2_8_45_1","unstructured":"ReddyKR EversonGT FlammSL DenningJM ArterburnS Brandt\u2010SarifT et al.Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective multicenter study. [abstract 8] [Abstract presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2014."},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu731"},{"key":"e_1_2_8_47_1","unstructured":"KhatriA WangT WangH PodsadeckiTJ TrinhR AwniWM et al.Drug\u2013drug interactions of the direct acting antiviral regimen of ABT\u2010450\/r ombitasvir and dasabuvir with HIV protease inhibitors. [abstract V\u2010484] [Abstract presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)]. Washington DC 2014."},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13111"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","unstructured":"KwoPY MantryP CoakleyEP TeH VargasH BrownRS et al.Results of the phase 2 study M12\u2010999: interferon\u2010free regimen of ABT\u2010450\/R\/ABT\u2010267\u00a0+\u00a0ABT\u2010333\u00a0+\u00a0ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. [abstract O114] [Abstract presented at the 49th Annual Meeting of the European Association for the Study of the Liver (ILC)]. London UK 2014.","DOI":"10.1016\/S0168-8278(14)60116-1"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27920"},{"key":"e_1_2_8_51_1","doi-asserted-by":"crossref","unstructured":"SekarV VerloesR MeyvischP SpittaelsK AkumaSH SmedtGD.Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. [abstract 1076] [Abstract presented at the 45th annual meeting of the European Association for the Study of the Liver (ILC)]. Vienna Austria 2010.","DOI":"10.1016\/S0168-8278(10)61077-X"},{"key":"e_1_2_8_52_1","unstructured":"Ouwerkerk\u2010MahadevanS SimionA MortierS.No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the mmunosuppressive agents cyclosporine and tacrolimus. [abstract 80] [Abstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2012."},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12438"},{"key":"e_1_2_8_54_1","doi-asserted-by":"crossref","unstructured":"Ouwerkerk\u2010MahadevanS VanwelkenhuysenI PeetersM SimontsM IlsbrouxI SimionA et al.Significant drug\u2013drug interaction between simeprevir and cyclosporine a but not tacrolimus in patients with recurrent chronic HCV infection after orthotopic liver transplantation: the SATURN study.[poster P0834] [Abstract presented at the 50th annual meeting of the European Association for the Study of the Liver (ILC)]. Vienna Austria 2015.","DOI":"10.1016\/S0168-8278(15)31036-9"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.171"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12728"},{"key":"e_1_2_8_57_1","first-page":"1","article-title":"Chronic hepatitis C: future treatment","volume":"6","author":"Wendt A","year":"2014","journal-title":"Clin Pharmacol"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","unstructured":"DumortierJ Botta\u2010FridlundD CoillyA LeroyV Fougerou\u2010LeurentC DanjouH et al.Treatment of severe HCV\u2010recurrence after liver transplantation using sofosbuvir\u2010based regimens: the ANRS CO23 CUPILT study. [abstract O109] [Abstract presented at the 50th annual meeting of the European Association for the Study of the Liver (ILC)]. Vienna Austria 2015.","DOI":"10.1016\/S0168-8278(15)30128-8"},{"key":"e_1_2_8_59_1","unstructured":"JohnsonH LichvarAB RustgiVK.The effect of ledipasvir\/sofosbuvir on dose\u2010normalized levels of immunosuppression in liver transplant recipients. [abstract 1741] [Abstract presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. San Francisco CA 2015."},{"key":"e_1_2_8_60_1","unstructured":"BifanoM AdamczykR HwangC KandoussiH MarionA BertzR.Daclatasvir pharmacokinetics in healthy subjects: no clinically\u2010relevant drug\u2013drug interactions with either cyclosporine or tacrolimus. [abstract 1081] [Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Washington DC 2013."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0279-5"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12209"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.06.004"},{"key":"e_1_2_8_64_1","doi-asserted-by":"crossref","unstructured":"CoillyA FougerouC LedinghenVD Houssel\u2010DebryP DuvouxC MartinoVD et al.The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort. [abstract G15] [Abstract presented at the 50th annual meeting of the European Association for the study of the liver (ILC)]. Vienna Austria 2015.","DOI":"10.1016\/S0168-8278(15)30103-3"},{"key":"e_1_2_8_65_1","unstructured":"Ouwerkerk\u2010MahadevanS BeumontM PeetersM SpittaelsK SekarV.The pharmacokinetic interaction between the investigational NS3\/4\u00a0A HCV protease inhibitor TMC435 and escitalopram. [abstract 1354] [Abstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2012."},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K615"},{"key":"e_1_2_8_67_1","unstructured":"PolepallyAR JenniferK DingB ShusterD DumasE KhatriA et al.Drug\u2013drug interactions of commonly used medications with direct acting antiviral HCV combination therapy of paritaprevir\/r ombitasvir and dasabuvir. [abstract 16] [Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy]. Washington DC 2015."},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01778-15"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100054"},{"key":"e_1_2_8_70_1","unstructured":"Ouwerkerk\u2010MahadevanS SekarV PeetersM Beaumont\u2010MauvielM.The pharmacokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine tenofovir efavirenz or raltegravir in healthy volunteers. [abstract 49] [Abstract presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI)]. Seattle WA 2012."},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000034"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2674"},{"key":"e_1_2_8_73_1","unstructured":"MenonRM.Ombitasvir\/paritaprevir\/ritonavir + dasabuvir: drug interactions with antiretroviral agents.[Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy]. Washington DC 2015."},{"key":"e_1_2_8_74_1","unstructured":"KirbyB MathiasA RossiS MoyerC ShenG KearneyBP.GS\u20107977 & HIV ARTs PK \u2010 no clinically significant pharmacokinetic interactions between sofosbuvir (GS\u20107977) and HIV antiretrovirals atripla rilpivirine darunavir\/ritonavir or raltegravir in healthy volunteers. [abstract 1877] [Abstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2012."},{"key":"e_1_2_8_75_1","unstructured":"MenonRM BadriPS KhatriA WangT PolepallyAR PodsadeckiTJ.ABT\u2010450\/ritonavir +ombitasvir + dasabuvir: drug interactions mediated by transporters. [Abstract presented at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy]. Washington DC 2014."},{"key":"e_1_2_8_76_1","unstructured":"JohnsonH BrownMA LichvarAB DunnMA ChopraKB.Effect of simeprevir administration on dose\u2010normalized concentration of calcineurin inhibitors in solid organ transplant recipients with hepatitis C infection. [abstract 1754] [Abstract presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. San Francisco CA 2015."},{"key":"e_1_2_8_77_1","unstructured":"EleyT YouX HuangS SymondsWT LiW ShermanD et al.Evaluation of drug interaction potential between daclatasvir and sofosbuvir. [abstract O_14] [Abstract presented at the 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy]. Cambridge MA 2013."},{"key":"e_1_2_8_78_1","unstructured":"GermanP MathiasA PangPS ShenG VimalM SymondsWT et al.Lack of a clinically significant pharmacokinetic drug\u2010drug interaction between sofosbuvir (GS\u20107977) and GS\u20105885 or GS\u20109669 in healthy volunteer. [abstract 1888] [Abstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2012."},{"key":"e_1_2_8_79_1","unstructured":"MogalianE GermanP BrainardDM LinkJ McNallyJ HanL et al.Lack of a clinically significant pharmacokinetic drug\u2010drug interaction between sofosbuvir and GS\u20105816 in healthy volunteers. [abstract 465]. [Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Washington DC 2013."},{"key":"e_1_2_8_80_1","unstructured":"SongI JervaF ZongJ ChoukourM WynneB BuchananA et al.Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects. [abstract 79] [Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy]. Washington DC 2015."},{"key":"e_1_2_8_81_1","unstructured":"EleyT LiW HuangS HeB ChungE GriffiesA et al.Evaluation of pharmacokinetic drug drug interaction between BMS\u2010 791325 an NS5B non\u2010nucleotide polymerase inhibitor daclatasvir and asunaprevir in triple combination in HCV genotype 1 infected patients. [abstract O_18] [Abstract presented at the 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy]. Cambridge MA 2013."},{"key":"e_1_2_8_82_1","unstructured":"YehW FraserIP BifanoM CaroL TalatyJ GuoZ et al.Lack of pharmacokinetic interaction between HCV protease inhibitor MK-5172 and HCV NS5A inhibitor daclatasvir in healthy volunteers. [abstract 464] [Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. washington DC 2013."},{"key":"e_1_2_8_83_1","unstructured":"BadriP ParikhA CoakleyE DingB AwniW DuttaS et al.Pharmacokinetics of cyclosporine and tarcolimus following coadministration with the direct acting antiviral combination ABT450 ombitasvir and dasabuvir in liver transplant patient with genotype 1 HCV infection. [Abstract presented at the 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)]. Boston MA 2014."},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.729577"},{"key":"e_1_2_8_85_1","unstructured":"PolepallyAR BadriPS ParikhA RodriguesL Da Silva\u2010TillmannBA MensingS et al.Effect of comedications on paritaprevir ritonavir ombitasvir dasabuvir and ribavirin pharmacokinetics.[Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy]. Washington DC 2015."},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.029"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2014.0215"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141164"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.020"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.032"},{"key":"e_1_2_8_91_1","unstructured":"GandhiY AdamczykR WangR StonierM KandoussiH HesneyM et al.Assessment of drug\u2013drug interactions between daclatasvir and darunavir\/ritonavir or lopinavir\/ritonavir. [abstract 80] [Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy]. Washington DC 2015."},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2015.0004"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.998997"},{"key":"e_1_2_8_94_1","unstructured":"TaburetAM PirothL PaniezH SimonyM FurlanV Barrail\u2010TranA et al.Pharmacokinetics of asunaprevir daclatasvir and raltegravir in HCV\/HIV co infected patients with or without cirrhosis and previously null responders to pegylated interferon + ribavirin (ANRS HC30 \u2010 QUADRIH study). [abstract 1967] [Abstract presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2014."},{"key":"e_1_2_8_95_1","doi-asserted-by":"crossref","unstructured":"CornpropstM DenningJ ClemonsD MarburyTC AlcornH SmithW et al.The effect of renal impairment and end stage renal disease on the single\u2010dose pharmacokinetics of PSI\u20107977. [abstract 1101] [Abstract presented at the 47th Annual Meeting of the European Association for the Study of the Liver (ILC)]. Barcelona Spain 2012.","DOI":"10.1016\/S0168-8278(12)61113-1"},{"key":"e_1_2_8_96_1","unstructured":"GaneE RobsonR BonaciniM MaliakkalB KirbyB LiuL et al.Safety antiviral efficacy and pharmacokinetics of sofosbuvir in patients with severe renal impairment. [Abstract presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2014."},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.004"},{"key":"e_1_2_8_98_1","doi-asserted-by":"crossref","unstructured":"LawitzE Rodriguez\u2010TorresM CornpropstM DenningJ ClemonsD McNairL et al.The effect of hepatic impairment on the safety pharmacokinetics and antiviral activity of GS\u20107977 in hepatitis C infected subjects treated for seven days. [abstract 1130] [Abstract presented at the 47th annual meeting of the European Association for the Study of the Liver (ILC)]. Barcelona Spain 2012.","DOI":"10.1016\/S0168-8278(12)61142-8"},{"key":"e_1_2_8_99_1","unstructured":"GermanP MathiasA YangJC McNairL ShenG VimalM et al.The pharmacokinetics of ledipasvir an HCV specific NS5A inhibitor in HCV\u2010uninfected subjects with moderate and severe hepatic impairment. [abstract 467] [Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Washington DC 2013."},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0314-y"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13343"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.029"},{"key":"e_1_2_8_103_1","first-page":"S590","article-title":"Sofosbuvir\u2010containing regimen for HCV infection in hemodialysis patients: 400\u00a0mg daily or only on the day of hemodialysis","volume":"62","author":"Desnoyer A","journal-title":"J Hepatol"},{"key":"e_1_2_8_104_1","doi-asserted-by":"crossref","unstructured":"MogalianE MathiasA YangJ MooreheadL HernandezM LasseterK et al.The pharmacokinetics of ledipasvir an HCV\u2010specific NS5A inhibitor in HCV\u2010uninfected subjects with severe renal impairment.[Abstract presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2015.","DOI":"10.1016\/S0168-8278(15)30915-6"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-015-0101-0"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2941"},{"key":"e_1_2_8_107_1","unstructured":"GarimellaT WangR LuoWL HwangC ShermanD KandoussiH et al.The effect of renal impairment on single\u2010dose pharmacokinetics of daclatasvir an HCV NS5A inhibitor. [Abstract presented at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis therapy]. Washington DC 2014."},{"key":"e_1_2_8_108_1","doi-asserted-by":"crossref","unstructured":"PockrosPJ ReddyKR MantryPS CohenE BennettM SulkowskiMS et al.Safety of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end\u2010stage renal disease: the RUBY\u2010I study. [abstract L01] [Abstract presented at the 50th annual meeting of the European Association for the Study of the Liver (ILC)]. Vienna Austria 2015.","DOI":"10.1016\/S0168-8278(15)30147-1"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv361"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12642"},{"key":"e_1_2_8_111_1","unstructured":"BifanoM SevinskyH StonierM JiangH BertzRJ.Daclatasvir an HCV NS5A replication complex inhibitor has minimal effect on pharmacokinetics of midazolam a sensitive probe for cytochrome P450 3\u00a0A4. [abstract O_15] [Abstract presented at the 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy]. Cambridge MA 2013."},{"key":"e_1_2_8_112_1","unstructured":"Ouwerkerk\u2010MahadevanS Beaumont\u2010MauvielM PeetersM AkumaSH SekarV.The pharmacokinetic interaction between the investigational NS3\/4\u00a0A HCV protease inhibitor TMC435 and methadone. [abstract 1353] [Abstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2012."},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2718"},{"key":"e_1_2_8_114_1","unstructured":"Ouwerkerk\u2010MahadevanS SimionA SpittaelsK PeetersM Beaumont\u2010MauvielM.No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone. [abstract 773] [Abstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)]. Boston MA 2012."},{"key":"e_1_2_8_115_1","unstructured":"KiserJ.The clinical pharmacology of therapy for hepatitis.[Abstract presented at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy]. Washington DC 2014."},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.031"},{"key":"e_1_2_8_117_1","unstructured":"BifanoM HwangC OostrerhuisB HartstraJ TiessenRG Velinova\u2010DongaM et al.Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS\u2010790052 demonstrates a pharmacokinetic profile which supports co\u2010administration with tenofovir disoproxil fumarate efavirenz and atazanavir\/ritonavir. [abstract 618] [Abstract presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI)]. Seattle Wa 2012."},{"key":"e_1_2_8_118_1","unstructured":"KhatriA TrinhR ZhaoJ PodsadeckiT MenonR.Drug\u2013drug interactions of ombitasvir\/paritaprevir\/r plus dasabuvir with dolutegravir or abacavir plus lamivudine.[Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy]. Washington DC USA 2015."},{"key":"e_1_2_8_119_1","unstructured":"DesnoyerA L\u00eaMP BelissaE PainJB GervaisA ChasJ et al.Therapeutic drug monitoring of daclatasvir in HIV\/HCV coinfected patients receiving darunavir\/ritonavir 800\/100 mg once\u2010daily. [Abstract presented at the16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy]. Washington DC 2015."},{"key":"e_1_2_8_120_1","unstructured":"Ouwerkerk\u2010MahadevanS SekarV SimionA PeetersM Beaumont\u2010MauvielM.The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. [abstract 1618] [Abstract presented at the Infectious Diseases Society of America (IDSA) Annual Meeting]. San Diego 2012."},{"key":"e_1_2_8_121_1","unstructured":"GermanP GarrisonK PangPS StammLM RayAS ShenG et al.Drug\u2013drug interactions between anti\u2010HCV regimen ledipasvir\/sofosbuvir and antiretrovirals. [abstract 82] [Abstract presented at the Conference on Retroviruses and Opportunistic Infections]. Seattle 2015."},{"key":"e_1_2_8_122_1","unstructured":"GarrisonK CustodioJ PangP DasM ChengF MaG et al.Drug interactions between anti\u2010HCV antivirals ledipasvir\/sofosbuvir and integrase strand transfer inhibitor\u2010based regimens. [abstract 71] [Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy]. Washington DC 2015."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13095","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13095","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:41:51Z","timestamp":1695516111000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,26]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/bcp.13095"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13095","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,26]]}}}